Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPAG-ITP: eltrombopag + dexamethasone versus dexamethasone in newly diagnosed adult immune thrombocytopenia
2019-002658-21Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in immune thrombocytopenia (ITP) comparing Eltrombopag + dexamethasone with Dexamethasone (2 arms). Primary endpoint: Sustained response off treatment at 52 weeks. Started Jan 2020; status: completed.
02
Drugs
eltrombopagdexamethasone
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2019-002658-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002658-21.